ARTHUR CAPLAN received the 2014 Public Service Award from the National Science Board. Caplan is the founding head of the Division of Bioethics at New York University Langone Medical Center.
THE OHIO STATE UNIVERSITY signed a licensing agreement with MedVax Technologies Inc., for the licensing of cancer peptide vaccine technologies.
F. MARC STEWART was named incoming president of the board of directors of both the Patient Advocate Foundation and National Patient Advocate Foundation. Stewart has been a member of the foundation’s scientific board since 2003. Since 2000, he has been a professor of medical oncology at the University of Washington Medical School, medical director for... […]
KENNETH PIENTA was named director of the Prostate Cancer Program at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. He is joined by two co-directors, Samuel Denmeade and Shawn Lupold.
VICTOR FAZIO and HAGOP KANTARJIAN will each receive lifetime achievement awards from Castle Connolly Medical Ltd. during their National Physician of the Year Awards, scheduled March 31 in New York City.
Sometimes a funding increase can be no increase at all.
Addressing the Molecular and Genetics Screening Panel, David Ransohoff, coauthor of the NEJM paper, focused on the future role of noninvasive tests like Cologuard in programs of screening for colorectal cancer.
The Panel's Comments“I typically refrain from commentary, but I will say this: I think this is a phenomenal study, in particular, for one reason,” said FDA panel member Ronald Przygodzki, acting director of Biomedical Laboratory Research and Development at the Department of Veterans Affairs Office of Research & Development.
The FDA Molecular and Clinical Genetics Panel voted 10-0 to recommend approval of Cologuard—a noninvasive, multitarget stool DNA screening test for colorectal cancer.
MD ANDERSON CANCER CENTER signed a three-year translational and clinical research agreement with MedImmune to develop anti-cancer immunotherapies through the center's Moon Shots Program. MedImmune is the global biologics research and development arm of AstraZeneca.
